Jump Financial LLC Grows Position in Zoetis Inc. $ZTS

Key Points

• Jump Financial LLC increased its position in Zoetis Inc. by 146.5% in the first quarter, acquiring a total of 131,600 shares worth approximately $21.67 million.
• In its most recent earnings report, Zoetis posted earnings per share of $1.76, surpassing the analysts' expectation of $1.62, alongside a revenue of $2.46 billion.
• Analysts have mixed ratings on Zoetis, with a consensus of "Moderate Buy" and a price target averaging $202.43.

Jump Financial LLC boosted its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 146.5% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 131,600 shares of the company's stock after purchasing an additional 78,208 shares during the period. Jump Financial LLC's holdings in Zoetis were worth $21,668,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of ZTS. Navigoe LLC purchased a new position in Zoetis during the fourth quarter valued at $30,000. Cornerstone Planning Group LLC raised its holdings in Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after acquiring an additional 88 shares during the period. Migdal Insurance & Financial Holdings Ltd. raised its holdings in Zoetis by 87.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after acquiring an additional 120 shares during the period. Sound Income Strategies LLC raised its holdings in Zoetis by 141.4% during the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after acquiring an additional 164 shares during the period. Finally, Bfsg LLC raised its holdings in Zoetis by 614.6% during the first quarter. Bfsg LLC now owns 293 shares of the company's stock valued at $48,000 after acquiring an additional 252 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Trading Up 0.5%

Shares of ZTS stock opened at $156.3180 on Friday. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock's 50-day moving average price is $153.84 and its 200-day moving average price is $158.64. The stock has a market capitalization of $69.28 billion, a price-to-earnings ratio of 26.91, a price-to-earnings-growth ratio of 2.50 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. During the same period in the previous year, the firm posted $1.56 earnings per share. The business's revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president directly owned 15,129 shares of the company's stock, valued at $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.18% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and decreased their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Piper Sandler raised their price target on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Finally, UBS Group decreased their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $202.43.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.